Month: April 2021

Based on Atos’ BullSequana XH2000, the ‘Vega’ supercomputer was inaugurated at the Institute of Information Science (IZUM) in Slovenia Maribor (Slovenia), Paris (France) April 21, 2021 – Atos and the Institute of Information Science (IZUM) in Maribor, Slovenia, today announce that the first EuroHPC supercomputer is now operational. This is the ‘Vega’ supercomputer, based on Atos’ BullSequana XH2000 architecture, which is now installed following a start-up ceremony hosted by IZUM with the Prime Minister of the Republic of Slovenia, Janez Janša, in attendance, together with the Executive Vice-President of the European Commission Margrethe Vestager, the Minister of Education, Science and Sport Dr. Simona Kustec and the Executive Director of EuroHPC Joint Undertaking Anders Dam Jensen. Vega, the largest supercomputer in the country, is based...

Basé sur le BullSequana XH2000 d’Atos, le supercalculateur « Vega » a été inauguré à l’Institut des sciences de l’information (IZUM) en Slovénie  Maribor (Slovénie), Paris (France) 21 avril 2021 – Atos et l’Institut des Sciences de l’Information (IZUM) de Maribor, en Slovénie, annoncent aujourd’hui que le premier supercalculateur EuroHPC est désormais opérationnel. Baptisé Vega, ce supercalculateur repose sur l’architecture BullSequana XH2000 d’Atos. Il a été inauguré lors d’une cérémonie organisée par IZUM, en présence du Premier ministre slovène, Janez Janša, ainsi que de la Vice-présidente exécutive de la Commission européenne, Margrethe Vestager, de la Ministre de l’éducation, des sciences et des sports, Simona Kustec, et du Directeur exécutif de l’entreprise commune EuroHPC,...

PRESS RELEASE, Värnamo 21 April 2021 The Board of Directors of Bufab AB (publ) (“Bufab”) has resolved, pursuant to the authorisation granted by the annual general meeting held on 20 April 2021, to repurchase the company’s own shares on Nasdaq Stockholm. The purpose of the repurchase is to hedge Bufab’s future delivery of shares to the participants of Bufab’s long-term call option program which was resolved by the 2021 annual general meeting. The repurchase may commence on 11 May 2021 and will be administered by Svenska Handelsbanken AB, which will take trading decisions independently of Bufab with regard to the timing of the repurchases. However, no acquisitions will be made during a 30-day period prior to the announcement of a financial report. Purchases may comprise a maximum of 350,000 shares and may take place on one or several occasions...

PRESS RELEASE, Värnamo 21 april 2021 Styrelsen i Bufab AB (publ) (”Bufab”) har beslutat, med stöd av bemyndigandet från årsstämman den 20 april 2021, att förvärva egna aktier på Nasdaq Stockholm. Syftet med återköpet är att säkerställa framtida leverans av aktier till deltagarna i Bufabs långsiktiga köpoptionsprogram som beslutades av årsstämman 2021. Återköpet får inledas tidigast den 11 maj 2021 och kommer att förvaltas av Svenska Handelsbanken AB som fattar sina handelsbeslut vad avser de tidpunkter då återköpen sker oberoende av Bufab. Förvärv får ske av högst 350 000 aktier vid ett eller flera tillfällen, dock längst till årsstämman 2022. Återköp ska ske på Nasdaq Stockholm i enlighet med dess Regelverk för emittenter. Återköpen kommer att ske till ett pris inom det vid var tid registrerade kursintervallet, varmed avses intervallet...

Fondsbørsmeddelelse nr. 10/2021 Eksport giver cBrains omsætning et ekstra løft København, 21. april 2021 Resume cBrain er kommet rigtig godt fra start i 2021, både i Danmark og internationalt. Det interne regnskab for første kvartal 2021 viser en omsætningsvækst på 30% i forhold til samme periode sidste år. Dette er baseret på en fortsat vækst i salg af softwareabonnementer samt en væsentlig øget eksportandel. På det danske marked har cBrain i første kvartal annonceret en række nye kunder, samtidig med at aktiviteterne hos de eksisterende kunder fortsat øges. I den forbindelse kan cBrain bl.a. glæde sig over, at det på kort tid er lykkedes at levere en række nye løsninger til Miljøstyrelsen, som understøtter klimaindsatsen. Internationalt kan cBrain glæde sig over, at finansministeriet i De Forenede Arabiske Emirater har nomineret en...

Oslo, Norway, April 21, 2021 The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2020 and the report is attached. The Annual Report 2020 is also available on the company’s website www.pcibiotech.com. For further information, please contact:        PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo        Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429        Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 940 05 757 About PCI Biotech        PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES As live attendance of sporting events begins to resume in 2021, the Company has entered into an agreement in which TAAT™ will sponsor PBR bull riding events in the United States. With more than three million attendees per year and millions of viewers of PBR events broadcast globally, the Company anticipates that this sponsorship can be an integral part of its marketing strategy to cultivate awareness among smokers aged 21+. PBR sponsorships have proven to be extremely effective, with 54% of PBR fans being more likely to recognize a sponsor brand than the average U.S. adult, and 12% of fans having made a purchase from a company specifically because it was a PBR sponsor. LAS VEGAS and VANCOUVER, British Columbia, April 21, 2021 (GLOBE NEWSWIRE)...

HAMILTON, Ontario, April 21, 2021 (GLOBE NEWSWIRE) — Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) (“Reliq” or the “Company”), a rapidly growing global telemedicine company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, today announced that it has signed contracts with two US Nephrology practices to use Reliq’s proprietary iUGO Care platform to monitor Chronic Kidney Disease (CKD) patients. “It is exciting to see the rapidly increasing demand for Reliq’s iUGO Care platform with specialists in the US,” said Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc. “As the US begins to open up thanks to a successful COVID-19 vaccine rollout, we are increasing the number of patients we onboard to our platform every week and signing new contracts with clients in...